An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sanofi. Recruiting at 18 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Sanofi · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is one of 4 that started in 2025, is one of 3 observational ones, and was the 9th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 40+
Sanofi · Sites in France
Ages 18+
Sanofi · Sites in United States, Argentina, Austria and 19 more countries
Ages 40–85
Sanofi · Sites in United States, Argentina, Australia and 23 more countries
Ages 40–80
Sanofi · Sites in United States, Argentina, Belgium and 22 more countries
Ages 40–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 350 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 937 across the 12 interventional studies, 350 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.
Non-interventional Study. Patients receive Dupilumab in accordance with the summary of product characteristics in a real-world setting. The Dupilumab initiation must be independent of the study recruitment and patient data is documented based on clinical routine.
Participants will be screened, enrolled, and documented by their treating physician. To avoid any selection bias, all eligible participants will be invited to participate in this study in the order in which their eligibility is determined (consecutive recruitment). Participants will be treated within clinical routine practice and according to the current standard of care. Participants who permanently discontinue dupilumab treatment and therefore terminate the study prior to the last visit at month 24 will be requested to complete an Early Termination visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.
Change from Baseline in COPD Assessment Test (CAT) Score
The COPD Assessment Test (CAT) is a questionnaire to assess the health status and quality of life of people with COPD. The questionnaire consists of eight simple statements, which participants answer using a numerical scale. The CAT score ranges from 0 to 40, with lower scores indicating a better health status.
Time frame: Baseline up to 12 months
Change from Baseline in CAT Score
The COPD Assessment Test (CAT) is a questionnaire to assess the health status and quality of life of people with COPD. The questionnaire consists of eight simple statements, which participants answer using a numerical scale. The CAT score ranges from 0 to 40, with lower scores indicating a better health status.
Time frame: Baseline to up to 6 months and 24 months
Analysis of Socio-demographics, Medical Disease and Treatment History
Demographic data (age, sex \[f/m\], ethnicity, height, weight, BMI, vaccination status, smoking status, pack years) will be collected.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Exacerbations
Number and severity grade of exacerbations in the year before study start will be assessed.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Lung Function Parameters
Lung function parameters such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC), residual volume (RV), sRtot, Diffusing capacity of the lungs for carbon monoxide (DLCO), DLCO/VA, Rtot, oxygen saturation in the blood will be assessed.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Eosinophils [EOS] Levels
Analysis of clinical disease characteristics including EOS levels.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Fractional Exhaled Nitric Oxide [FeNO] Levels
Analysis of clinical disease characteristics including FeNO levels.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Immunoglobulin E [IgE] Levels
Analysis of clinical disease characteristics including IgE levels.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) Grade and Group
Analysis of clinical disease characteristics including current GOLD grade and group.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Smoking Status and Pack Years
Analysis of clinical disease characteristics including smoking status and pack years.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Comorbidities
Current and previous comorbidities (such as chronic rhinosinusitis, asthma, allergies, or cardiovascular comorbidities) will be assessed.
Time frame: Baseline
Analysis of Clinical Disease Characteristics including Date of COPD Diagnosis and GOLD Grade/Group at COPD Diagnosis
Analysis of clinical disease characteristics including date of COPD diagnosis and GOLD grade/group at COPD diagnosis.
Time frame: Baseline
Annualized Rate of Moderate and Severe COPD Exacerbations
Annualized rate of moderate and severe COPD exacerbations after 12 and 24 months versus the year before baseline.
Time frame: Baseline to up to 12 and 24 months
Change in Rate of Moderate and Severe Exacerbations
Change in rate of moderate and severe exacerbations will be assessed.
Time frame: Baseline to up to 6, 12 and 24 months
Time to First Moderate or Severe Exacerbation Since Study Start
Time to first moderate or severe exacerbation since study start.
Time frame: Baseline to up to 6, 12 and 24 months
Cumulative Moderate and Severe Exacerbations Over Time
Cumulative moderate and severe exacerbations over time
Time frame: Baseline to up to 6, 12 and 24 months
Change Over Time in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Change over time in pre- and post-bronchodilator FEV1 from study start.
Time frame: Baseline to up to 6, 12 and 24 months
Change Over Time in Bronchodilator FEV1/Forced Vital Capacity (FVC)
Change over time in pre- and post- bronchodilator FEV1/FVC from study start.
Time frame: Baseline to up to 6, 12 and 24 months
Change Over Time in Modified Medical Research Council (mMRC)
Change over time in mMRC from study start.
Time frame: Baseline to up to 6, 12 and 24 months
Number of Missed Workdays due to COPD
Number of missed workdays due to COPD during the last year before baseline and after dupilumab treatment.
Time frame: Baseline to up to 6, 12 and 24 months
Number of Hospitalization After Dupilumab Treatment
Number of hospitalizations after dupilumab treatment versus the year before study start.
Time frame: Baseline to up to 6, 12 and 24 months
Reason(s) for Initiation of Dupilumab Treatment
Reason(s) for initiation of dupilumab treatment will be evaluated.
Time frame: Baseline
Frequency of Adverse Events (AEs) During the Observation Period
Frequency of AEs will be evaluated during the observation period.
Time frame: Baseline to up to 24 months
Type of AEs
Type of AEs will be evaluated during the observation period.
Time frame: Baseline to up to 24 months
Frequency of Possible Dupilumab-Related Treatment Emergent AEs (TEAEs)
Frequency of possible dupilumab-related TEAEs will be evaluated during the observational period.
Time frame: Baseline to up to 24 months
Type of Possible Dupilumab-Related TEAEs
Type of possible dupilumab-related TEAEs will be evaluated during the observational period.
Time frame: Baseline to up to 24 months
Occurrence of Product Technical Complaints (PTCs)
Occurrence of PTCs will be evaluated.
Time frame: Baseline to up to 6, 12 and 24 months
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.
Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 48 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →